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Let’s End It is the theme of this year’s World AIDS Day, which falls on December 1. In the
spirit of the event, PLOS Medicine is devoting this special issue to a discussion on advances in
HIV prevention, treatment, and cure. Here, we describe many of the remaining barriers in
ending the epidemic and highlight a number of accompanying studies that provide paths for-
ward for overcoming some of these challenges.
An estimated 75 million people have acquired HIV infection since the first reports of infec-
tion in the 1970s. Over 35 million people have died. With the advent of combination antiretro-
viral therapy (ART) in 1996, the life expectancy of HIV-infected adults in both high- and low-
income countries now approaches that of the general population but only in people who start
therapy early in the disease process, who take therapy on a daily basis, and who have life-long
access to drugs and monitoring of antiviral effects. The remarkably successful and ongoing
global effort to provide treatment means that 20.9 million of the estimated 36.7 million people
living with HIV globally are now receiving therapy [1]. ART not only improves health but it
makes a person noninfectious; HIV-infected mothers on effective ART rarely transmit HIV to
their infants, and HIV-infected adults on effective ART have been shown to not transmit the
virus to their sexual partners. The significance of these achievements cannot be overstated: in
the past 3 decades, global biomedical and public health programs not only discovered how
HIV causes disease and developed effective strategies to prevent and treat the infection, but
also built a global public health response that is unprecedented in its scale and effectiveness.
ART is the mainstay of treatment for people with HIV infection, and a crucial component
of UNAIDS’s global aims to achieve, by 2020, high proportions (90%) of people, respectively,
tested for HIV infection, receiving ART, and with viral suppression (the so-called 90-90-90 ini-
tiative) [2]. Despite massive international efforts to achieve this goal, many challenges remain,
particularly as many of the key affected populations are highly stigmatized and marginalized.
In this issue of PLOS Medicine, various experts address aspects of the challenges facing infants
[3], children and adolescents [4], female sex workers [5–7], transgender women [8], men who
have sex with men (MSM), and people who inject drugs [9].
In a Perspective on these issues, Wafaa El-Sadr and colleagues discuss the important topic
of differentiated service delivery by which process interventions are combined and blended as
appropriate for individual populations and settings [10]. As an example, Margaret McNairy
and colleagues report on a cluster-randomized trial done in Swaziland [11] testing a combina-
tion intervention including point-of-care CD4 testing, prompt initiation of ART, and support-
ive components intended to improve adherence. The trial’s results show substantial benefits
in the trial’s primary endpoint of linkage to and retention in care at 1 year, indicating the
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Harsh political realities can also be a barrier; this is perhaps best illustrated in the intensify-
ing crisis that is the HIV epidemic in the Russian Federation, discussed in a Perspective by
Chris Beyrer and coauthors [13]. Here, as occurred in other countries earlier in the global epi-
demic with disastrous results, HIV infections are multiplying in key populations that lack soci-
etal attention and are denied proven healthcare interventions. In the Russian Federation and
other regions where anachronistic policies and laws in relation to injection drug use and MSM
fuel the spread of HIV, immediate action is needed to reverse the growth of local epidemics.
Biomedical methods to prevent HIV acquisition have undergone a resurgence in research
and development in the last decade with the demonstration that ART given either as pre-expo-
sure prophylaxis (for an uninfected individual) or as treatment (for an infected individual) can
prevent transmission. Combination prevention packages are now being tailored for different
populations; these approaches often take a more holistic approach and include harm reduction
for people who inject drugs and social protection for young unemployed women.
Despite these advances, it is generally assumed that an effective vaccine will be needed to
ultimately end the spread of HIV. In another Perspective, Lynn Morris and Nonhlanhla
Mkhize discuss the prospects for broadly neutralizing antibodies (BNAbs) to contribute to
HIV prevention efforts by eliciting passive immunity [14], and Ken Mayer and colleagues
report a phase 1 trial of VRC01, a BNAb that is proceeding to large-scale evaluation [15]. It is
hoped that such BNAb studies might identify novel therapies for prevention and provide
important insights for the development of more scalable vaccines. Whether by generating
active or passive immunity, supplementing the available prevention strategies with an effective
vaccine remains of critical importance in circumventing the issues of adherence that affect
many current approaches, with potentially transformative benefits in specific settings and
populations.
For those who can access ART, residual concerns persist. For example, for reasons that
remain largely undefined, HIV-infected adults on otherwise effective therapy have an excess
risk of developing a number of non-AIDS complications. These complications include cardio-
vascular disease and kidney disease, and in a study based on the D:A:D collaboration, Mark
Boyd and colleagues describe a multiplicative increase in events in people at high risk of car-
diovascular and renal disease [16], which has implications for long-term management.
Due in part to problems in retaining people in care and the apparent inability of ART to
fully restore health [16], there is now a major global scientific effort to find a cure for HIV dis-
ease. Although ART prevents HIV from replicating, it does not eliminate a stable reservoir of
infected cells that persists indefinitely. Approaches to reducing this reservoir include starting
ART very early (before the reservoir is established) or reconstructing a new HIV-free immune
system through hematopoietic stem cell transplantation. Timothy Henrich and colleagues
report an extraordinary case of what happened when ART was initiated on essentially the first
day an infection might be diagnosed, estimated to be roughly 10 days post-infection [17]. The
reservoir of replication-competent virus in this individual was several orders of magnitude
lower than that observed when ART was started during chronic infection, but unfortunately
the person was not cured as, even during this brief period of time, approximately 200 stably
infected cells were established. A similar state of prolonged time to rebound, once ART was
stopped, was achieved in an HIV-infected individual who received an allogeneic stem cell
transplantation, as demonstrated by Andrew Badley and colleagues [18]. For the initial 10
months off ART, virus was undetectable but eventually rebounded. Careful sequencing of the
rebound virus did not match virus sequenced in blood prior to transplantation, highlighting
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the great challenge in understanding the main source of viral rebound off ART. Furthermore,
it is now clear that simply reducing virus, even by several logs, will not lead to durable remis-
sion without ART.
The aspirational slogan Let’s End It suggests that the goal of ending the epidemic is in our
grasp and hinges only on our collective commitment to do so. However, the remarkable prog-
ress, activism, resources, ingenuity, and sheer fortitude that have brought us this far will be
needed in at least equal measure to take us to the end. Only by harnessing the maximum avail-
able resources; innovating and implementing relentlessly; and applying the fruits of these pro-
cesses without prejudice to all human populations, wherever they are needed, will we be able
to start imagining an end to the HIV/AIDS epidemic.
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